Aera Therapeutics

Aera Therapeutics is a biotechnology company focused on the delivery problem in genetic medicines. The company states that payload technologies such as RNAi, mRNA, gene therapy and gene editing have advanced faster than the delivery systems needed to bring them to tissues beyond the liver or outside ex vivo settings, and it positions itself as a "delivery first" genetic medicines company that pairs next-generation delivery technologies with precision payloads optimized for specific diseases.

Aera operates three proprietary delivery platforms. Its targeted lipid nanoparticle (tLNP) platform is built on proprietary ionizable lipids intended to reach cell types and tissues beyond the liver and vaccine applications typical of current LNPs. Its antibody oligonucleotide conjugate (AOC) platform combines an antibody or antibody fragment for cell/tissue targeting, an oligonucleotide payload, and conjugation chemistry designed to preserve both antibody function and oligonucleotide activity, with stated applicability to cardiac and skeletal muscle. Its protein nanoparticle (PNP) platform, originating from research in the laboratory of scientific founder Feng Zhang at the Broad Institute of MIT and Harvard, uses endogenous human proteins derived from retroelements that self-assemble into capsid-like structures able to package and transfer nucleic acid cargo; Aera describes the PNPs as a fully synthetic, cell-free, modular system engineered for longer circulatory half-life when untargeted and for the addition of targeting ligands. At launch the company also described a licensed therapeutic enzyme platform based on novel, compact, programmable gene editing enzymes whose small size may ease packaging and delivery constraints.

The pipeline is preclinical. The lead program, AERA-109, is a targeted in vivo CAR-T therapy for B cell-mediated autoimmune diseases that uses the tLNP platform to generate CAR-T cells inside the body; it is described as in IND-enabling work with clinical entry expected in mid-2026 / the second half of 2026. Additional programs include next-generation targeted LNP programs (discovery), a cardiac-targeted AOC (lead optimization), other muscle-targeted AOC (discovery), and a CNS-targeted PNP (discovery).

Founding story

Aera was founded by a group of scientists, investors and company builders around the goal of unlocking genetic medicines by addressing delivery. Its scientific founder is Feng Zhang, Ph.D., core member of the Broad Institute of MIT and Harvard, McGovern Institute investigator, the James and Patricia Poitras Professor of Neuroscience at MIT and a Howard Hughes Medical Institute investigator; the company's initial protein nanoparticle delivery platform derives from research conducted in his laboratory. Akin Akinc, Ph.D., previously of Alnylam Pharmaceuticals, joined as chief executive officer in 2022, and the company emerged publicly in February 2023 with combined Series A and B financings.

Business model

Aera is a preclinical-stage therapeutics developer funded by venture capital. It builds proprietary delivery platforms and pairs them with payloads to create internal drug programs; the sources do not describe partnering, licensing or product revenue arrangements beyond the licensed therapeutic enzyme platform it in-licensed.

Traction

Preclinical. Data presented in September 2025 showed dose-dependent, specific in vivo CAR-T cell generation and deep B cell depletion in blood and tissues in humanized mouse models and non-human primates, supporting nomination of AERA-109 as the first development candidate, with clinical entry guided to mid-2026/second half of 2026. Other pipeline programs remain in discovery or lead optimization.

Latest developments

In March 2026 Mark McKee, M.D., joined as Senior Vice President, Clinical Development, from Intellia. The most recent disclosed program milestone is the September 2025 nomination of AERA-109 and its planned entry into clinical development in 2026.